- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.06. | Intelligent Bio Solutions starts interference study for FDA submission | 1 | Investing.com | ||
| 16.06. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | 215 | GlobeNewswire (Europe) | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| 02.06. | Intelligent Bio Solutions starts FDA study for fingerprint drug test | 2 | Investing.com | ||
| 02.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.05. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year | 208 | GlobeNewswire (Europe) | Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building... ► Artikel lesen | |
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 13.05. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results | 266 | GlobeNewswire (Europe) | Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach... ► Artikel lesen | |
| 20.04. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | INBS completes penetration testing for FDA 510(k) submission | 5 | Investing.com | ||
| 17.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified | 371 | GlobeNewswire (Europe) | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 02.04. | INBS completes clinical study for FDA drug screening submission | 3 | Investing.com | ||
| 02.04. | INBS schließt klinische Studie für FDA-Zulassungsantrag ab | 3 | Investing.com Deutsch | ||
| 02.04. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market | 218 | GlobeNewswire (Europe) | Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability... ► Artikel lesen | |
| 26.03. | Intelligent Bio Solutions receives European patent for drug testing tech | 1 | Investing.com | ||
| 26.03. | Intelligent Bio Solutions erhält europäisches Patent für Drogentest-Technologie | 5 | Investing.com Deutsch | ||
| 23.03. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 25.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.02. | INBS receives first reader shipment from Syrma Johari partnership | 3 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,890 | +0,40 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| DRAEGERWERK | 85,20 | +1,67 % | EQS-AFR: Drägerwerk AG & Co. KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Drägerwerk AG & Co. KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Drägerwerk AG & Co. KGaA: Vorabbekanntmachung... ► Artikel lesen | |
| TELADOC HEALTH | 8,458 | -0,17 % | Teladoc (TDOC) Rises Higher Than Market: Key Facts | ||
| HIMS & HERS HEALTH | 29,600 | -2,05 % | Truist reiterates Hold on Hims and Hers stock, $23 target on peptide uncertainty | ||
| BICO GROUP | 1,292 | -0,31 % | BICO Group AB: Bulletin from the Annual General Meeting in BICO Group AB (publ) | The following resolutions were passed at the Annual General Meeting (the "AGM") of BICO Group AB (publ) ("BICO" or the "Company") held today on 7 May 2026 in Gothenburg, Sweden.
Adoption of Income Statement... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,072 | +8,11 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,630 | -3,31 % | Geratherm Medical AG: Ein herausforderndes GJ26 folgt auf ein schwieriges GJ25; Kursziel gesenkt, KAUFEN. | Geratherm hat die Ergebnisse für das Geschäftsjahr 2025 veröffentlicht. Die Umsätze stiegen um 6 %, jedoch führten erhebliche makroökonomische Gegenwinde, Wettbewerb aus China und inländischer Kostendruck... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 159,75 | +0,73 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 06.07.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,010 | -16,39 % | NuGen Medical Devices Inc.: NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance | Toronto, Ontario--(Newsfile Corp. - May 28, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle free drug delivery, today announced the filing of a new... ► Artikel lesen | |
| PLUS THERAPEUTICS | 3,450 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding | Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide commercial progress HOUSTON, June 30... ► Artikel lesen | |
| HEALWELL AI | 0,463 | -0,64 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | -1,90 % | Rodman & Renshaw startet Coverage für Atossa Genetics mit Kaufempfehlung | ||
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae | ||
| SPINEWAY | 0,122 | 0,00 % | Spineway: First-quarter 2026 revenue | Ecully, April 30, 2026 - 6:00 p.m. First-quarter 2026 revenue High order volumeSlower-than-expected normalization of supply chains2026: growth trajectory confirmed In thousands of euros20262025Change... ► Artikel lesen |
INTELLIGENT BIO SOLUTIONS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,43 % bei einem Aktienkurs von 2,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTELLIGENT BIO SOLUTIONS INC finden Sie auf Wallstreet Online.